Subcutaneous Semaglutide in Systemic Scleroderma

Status Recruiting

Clinical Trial Summary

This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis

Clinical Trial Description

Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the cardiac, pulmonary, and gastrointestinal systems. This is a small prospective and open-label clinical trial of semaglutide in adults with systemic slceorsis. 10 systemic sclerosis patients will be recruited and receive semaglutide for 24 weeks. The primary endpoint of the study is the change in mRSS at 24 weeks of treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06149260
Study type	Interventional
Source	Second Xiangya Hospital of Central South University
Contact	Rong Xiao, MD
Phone	13808425555
Email	xiaorong65@csu.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	February 29, 2024
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05570058` - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis	Phase 2
Completed	`NCT03979417` - Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
Completed	`NCT02408744` - Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease	Phase 1/Phase 2
Active, not recruiting	`NCT00148837` - Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis	Phase 2
Recruiting	`NCT05661123` - Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis	N/A
Recruiting	`NCT04795570` - Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
Active, not recruiting	`NCT05075785` - Covid-19 Respiratory Sequelae French Cohort
Recruiting	`NCT03308916` - Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers	N/A
Recruiting	`NCT05459259` - Physiotherapy for Arthrofibrosis Following Knee Replacement.
Enrolling by invitation	`NCT01483248` - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis	Phase 1/Phase 2
Completed	`NCT00001729` - Combination Drug Therapy for Patients With Hepatitis C	Phase 3
Completed	`NCT02049307` - Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial	Phase 2
Active, not recruiting	`NCT05685823` - The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
Completed	`NCT00744939` - Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist	Phase 4
Completed	`NCT00252642` - Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C	N/A
Recruiting	`NCT04934202` - Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
Completed	`NCT02604862` - Imaging FIB ONE in the Human Lung Using Endomicroscopy	Early Phase 1
Completed	`NCT02774161` - B-mode Ultrasound Imaging in Detecting Early Liver Cancer	N/A
Active, not recruiting	`NCT01246388` - Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy	N/A
Completed	`NCT02161952` - Pirfenidone, an Antifibrotic and Antiinflammatory Drug	Phase 2